Changes in Hong Kong stocks | Fu Hong Han Lin (02696) rose more than 8%, and 8 research results will be unveiled at WCLC and Hans will enter the NHS health insurance system

The Zhitong Finance App learned that Fuhong Hanlin (02696) rose more than 8%, with a cumulative increase of more than 20% this week. As of press release, it rose 8.47% to HK$67.2, with a turnover of HK$28.224,400.

According to news, the 2026 World Lung Cancer Conference (WCLC) will be held from September 12 to 15 in Seoul, South Korea. Fu Hong Hanlin will present many of the latest research results of its innovative products at this conference, covering phase I research data on PD-L1ADCHLX43 in the field of thymic squamous cell carcinoma (TSCC), and 7 research data on the anti-PD-1 monoclonal H drug Hans form in the fields of broad-stage small cell lung cancer, limited-stage small cell lung cancer, and lung large cell neuroendocrine cancer.

It is worth noting that recently, the anti-PD-1 monoclonal antibody Hans form independently developed by Fu Hong Hanlin was recommended by the British National Institute of Health and Clinical Optimization (NICE) and is expected to enter the UK National Health Service (NHS) to benefit patients with extensive small cell lung cancer (ES-SCLC).